
Mohsen Karimi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6676707/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	LUMA (LUminometric Methylation Assay)—A high throughput method to the analysis of genomic DNA methylation. Experimental Cell Research, 2006, 312, 1989-1995.	1.2	261
2	Evaluating Variant Calling Tools for Non-Matched Next-Generation Sequencing Data. Scientific Reports, 2017, 7, 43169.	1.6	185
3	Using LUMA: a Luminometric-Based Assay for Global DNA-Methylation. Epigenetics, 2006, 1, 46-49.	1.3	146
4	Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML. Clinical Cancer Research, 2018, 24, 1834-1844.	3.2	136
5	p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q). Haematologica, 2014, 99, 1041-1049.	1.7	116
6	Global changes in DNA methylation in Alzheimer's disease peripheral blood mononuclear cells. Brain, Behavior, and Immunity, 2015, 45, 139-144.	2.0	112
7	Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes. Cell Reports, 2017, 20, 572-585.	2.9	99
8	The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts. Leukemia, 2013, 27, 889-896.	3.3	89
9	Differential methylation in CN-AML preferentially targets non-CGI regions and is dictated by <i>DNMT3A</i> mutational status and associated with predominant hypomethylation of HOX genes. Epigenetics, 2014, 9, 1108-1119.	1.3	74
10	SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells. Blood, 2017, 130, 881-890.	0.6	66
11	Gene expression and risk of leukemic transformation in myelodysplasia. Blood, 2017, 130, 2642-2653.	0.6	64
12	<i>microRNA-34b/c</i> on chromosome 11q23 is aberrantly methylated in chronic lymphocytic leukemia. Epigenetics, 2014, 9, 910-917.	1.3	43
13	Aberrant splicing of genes involved in haemoglobin synthesis and impaired terminal erythroid maturation in <i><scp>SF</scp>3B1</i> mutated refractory anaemia with ring sideroblasts. British Journal of Haematology, 2015, 171, 478-490.	1.2	37
14	Mutations in histone modulators are associated with prolonged survival during azacitidine therapy. Oncotarget, 2016, 7, 22103-22115.	0.8	37
15	Estimation of flotation rate constant and particle-bubble interactions considering key hydrodynamic parameters and their interrelations. Minerals Engineering, 2019, 141, 105836.	1.8	35
16	Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations. Haematologica, 2017, 102, 498-508.	1.7	34
17	appreci8: a pipeline for precise variant calling integrating 8 tools. Bioinformatics, 2018, 34, 4205-4212.	1.8	26
18	Perturbed hematopoietic stem and progenitor cell hierarchy in myelodysplastic syndromes patients with monosomy 7 as the sole cytogenetic abnormality. Oncotarget, 2016, 7, 72685-72698.	0.8	21

Mohsen Karimi

#	Article	IF	CITATIONS
19	Characterization of the Hematopoietic Stem and Progenitor Cell Hierarchy in Myelodysplastic Syndromes Patients with Monosomy 7 As the Sole Cytogenetic Abnormality. Blood, 2014, 124, 3490-3490.	0.6	16
20	A three-dimensional in vitro model of erythropoiesis recapitulates erythroid failure in myelodysplastic syndromes. Leukemia, 2020, 34, 271-282.	3.3	13
21	High-throughput mutational screening adds clinically important information in myelodysplastic syndromes and secondary or therapy-related acute myeloid leukemia. Haematologica, 2015, 100, e223-e225.	1.7	12
22	Male sex and the pattern of recurrent myeloid mutations are strong independent predictors of blood transfusion intensity in patients with myelodysplastic syndromes. Leukemia, 2019, 33, 522-527.	3.3	7
23	Increased cytomegalovirus replication by 5-Azacytidine and viral-induced cytoplasmic expression of DNMT‑1 in medulloblastoma and endothelial cells. International Journal of Oncology, 2018, 52, 1317-1327.	1.4	2
24	Mutations in Histone Modulators Are Associated with Prolonged Survival during Azacitidine Therapy. Blood, 2015, 126, 2839-2839.	0.6	0